Business Wire

Sutherland and ComplyAdvantage Launch AI-Native "Unified FinCrime Compliance" Solution to Combat Sophisticated, Next Generation Financial Crime

16.12.2025 15:00:00 CET | Business Wire | Press release

Share

New partnership merges Sutherland’s AI-native FinCrime expertise with ComplyAdvantage’s Mesh Risk Intelligence to deliver an integrated, modular AI-powered ecosystem for Fraud, AML, Risk and Transaction Monitoring.

Sutherland, a global leader in business and digital transformation, today announced a strategic partnership with ComplyAdvantage, a leading AI-driven risk intelligence platform. The collaboration introduces a comprehensive, AI-driven financial crime (FinCrime) management solution designed to help banks and Fintechs respond to the rapid rise of AI-designed fraud, complex AML risks, fast-evolving financial crime threats, and complex compliance requirements.

Today, financial crime requires sophisticated, AI-intelligence-based solutions, as traditional risk and compliance controls cannot keep up. The Sutherland-ComplyAdvantage solution transforms FinCrime management by delivering a single AI-native intelligence layer that continuously enhances screening, transaction monitoring, fraud prevention, case investigations, and regulatory reporting. This solution delivers consistent compliance, which is scalable and balances compliance and customer experience.

“Financial crime today behaves like an intelligent, adaptive network,” said Banwari Agarwal, CEO of Banking & Financial Services, Sutherland. “This partnership brings together AI, advanced analytics, and real-time intelligence to strengthen screening, monitoring, investigations, and operations. Our customers can now detect risk earlier, act faster, and operate with far greater accuracy and compliance.”

“The true hurdle in FinCrime isn’t piling on more tools—it’s architecting systems that scale seamlessly and intelligently,” said Doug Gilbert, CIO & Chief Digital Officer, Sutherland. “Through this partnership, we’re delivering a unified AI intelligence layer that spans data, models, and operations, empowering banks and fintechs to evolve their compliance programs with precision, speed, and zero added friction.”

The solution combines Sutherland’s 2,400+ FinCrime experts, AI-native digital accelerators, including Agentic AI, Sentinel AI, ID Scan, and HelpTree GenAI, and ComplyAdvantage’s Mesh, an AI-native platform that unifies customer and company screening, customer risk scoring, transaction monitoring, and real-time payments analysis in one intelligent system. Built on large language and predictive machine learning models that deliver superior detection and scoring, Mesh leverages agentic AI to learn, act, and adapt across the full compliance lifecycle.

The joint solution creates a unified intelligence layer. This allows financial institutions to:

  • Detect converging threats: Identify complex patterns that span both fraud and money laundering.
  • Respond in real-time: Move from reactive case management to immediate threat mitigation.
  • Unify the lifecycle: Monitor and respond to risk throughout the customer lifecycle, from onboarding to daily transactions, without data handoffs.

“The convergence of fraud, AML, and risk is the critical path forward for modern financial institutions,” said Vatsa Narasimha, CEO at ComplyAdvantage. “By bringing together our real-time risk intelligence and Sutherland’s digital transformation capabilities, we are empowering leaders to build FinCrime programs that are not just compliant, but actively resilient against the speed of new threats.”

Early enterprise deployments of the integrated solution have demonstrated tangible operational improvements, including:

  • 25% reduction in fraud losses.
  • 70% drop in false positives.
  • 90% improvement in compliance accuracy.
  • 50% faster investigations and alert remediation.
  • 99% payments screened in <0.5 seconds

About Sutherland

Artificial Intelligence. Automation. Cloud Engineering. Advanced Analytics.

For Enterprises, these are key factors of success. For us, they’re our core expertise.

We work with global iconic brands. We bring them a unique value proposition through market-leading technologies and business process excellence. At the heart of it all is Digital Engineering – the foundation that powers rapid innovation and scalable business transformation.

We’ve created 363 unique and independent inventions, 250 of which are AI-based and rolled up under several patent grants in critical technologies. Leveraging our advanced products and platforms, we drive digital transformation at scale, optimize critical business operations, reinvent experiences, and pioneer new solutions, all provided through a seamless “as-a-service” model.

For each company, we provide new keys for their businesses, the people they work with, and the customers they serve. With proven strategies and agile execution, we don’t just enable change — we engineer digital outcomes.

Know more:www.sutherlandglobal.com

About ComplyAdvantage

Our mission is to empower every business to eliminate financial crime.

By harnessing AI, a unified platform, and an extensive partner ecosystem, we help customers turn compliance into a catalyst for growth, operational resilience, and enduring regulatory trust.

More than 3,000 enterprises across 75 countries rely on our unified platform and the world’s most comprehensive financial crime risk intelligence. With full-stack agentic automation, we help organizations automate up to 95% of KYC, AML, and sanctions reviews, cut onboarding times by 50%, reduce false positives by 70%, and handle 7x more work with the same staff.

ComplyAdvantage is headquartered in London and has global hubs in New York, Lisbon, Singapore, and Cluj-Napoca. It is backed by Balderton Capital, Index Ventures, Ontario Teachers’ Pension Plan, Goldman Sachs, and Andreessen Horowitz. Learn more about compliance re-engineered for the age of AI atcomplyadvantage.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251216073992/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye